OTCMKTS:RPBC - Redpoint Bio Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0001 0.00 (0.00 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$0.0001
Today's Range$0.0001 - $0.0001
52-Week Range$0.0001 - $0.0023
Volume2,380 shs
Average Volume53,167 shs
Market Capitalization$7,992.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.

Receive RPBC News and Ratings via Email

Sign-up to receive the latest news and ratings for RPBC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RPBC
CUSIP757736103
Phone215-456-2312

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7,992.00
Next Earnings DateN/A
OptionableNot Optionable

Redpoint Bio (OTCMKTS:RPBC) Frequently Asked Questions

What is Redpoint Bio's stock symbol?

Redpoint Bio trades on the OTCMKTS under the ticker symbol "RPBC."

Has Redpoint Bio been receiving favorable news coverage?

Media headlines about RPBC stock have trended positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Redpoint Bio earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of Redpoint Bio's key competitors?

What other stocks do shareholders of Redpoint Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Redpoint Bio investors own include Twitter (TWTR), Hershey (HSY), Ferro (FOE), TowneBank (TOWN) and BMC Stock (BMCH).

Who are Redpoint Bio's key executives?

Redpoint Bio's management team includes the folowing people:
  • Dr. R. Kyle Palmer Ph.D., Sr. Director of Discovery Research

How do I buy shares of Redpoint Bio?

Shares of RPBC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Redpoint Bio's stock price today?

One share of RPBC stock can currently be purchased for approximately $0.0001.

How big of a company is Redpoint Bio?

Redpoint Bio has a market capitalization of $7,992.00.

What is Redpoint Bio's official website?

The official website for Redpoint Bio is http://www.redpointbio.com.

How can I contact Redpoint Bio?

Redpoint Bio's mailing address is 7 GRAPHICS DRIVE, EWING NJ, 08628. The company can be reached via phone at 215-456-2312.


MarketBeat Community Rating for Redpoint Bio (OTCMKTS RPBC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about Redpoint Bio and other stocks. Vote "Outperform" if you believe RPBC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPBC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel